Hyperprogression of advanced Melanoma Disease with Pembrolizumab adjuvant

被引：0
|
作者：
Geidel, G. [1 ]
Ammann, N. [1 ]
Schneider, S. W. [1 ]
Gebhardt, C. [1 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Dermatol & Venerol, D-20246 Hamburg, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2021年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
DK03/03
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [1] Adjuvant pembrolizumab-related hyperprogression in stage III melanoma
    Ammann, Nadine L.
    Geidel, Glenn
    Schneider, Stefan W.
    Gebhardt, Christoffer
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 (09): : 1341 - 1345
  • [2] Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant
    Geidel, Glenn
    Ammann, Nadine L.
    Schneider, Stefan W.
    Gebhardt, Christoffer
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 37 - 39
  • [3] Hyperprogression of submandibular melanoma following pembrolizumab therapy
    Muhammed, Amr
    Elnakib, Esraa
    Gamal, Walaa
    Roshdy, Shimaa
    Mahmoud, Aya
    Ahmed, Aya
    Mohamed, Ahmed El Sayed
    [J]. ORAL ONCOLOGY, 2023, 136
  • [4] Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
    Patel, Sapna P.
    Othus, Megan
    Chen, Yuanbin
    Wright, G. Paul
    Yost, Kathleen J.
    Hyngstrom, John R.
    Hu-Lieskovan, Siwen
    Lao, Christopher D.
    Fecher, Leslie A.
    Truong, Thach-Giao
    Eisenstein, Jennifer L.
    Chandra, Sunandana
    Sosman, Jeffrey A.
    Kendra, Kari L.
    Wu, Richard C.
    Devoe, Craig E.
    Deutsch, Gary B.
    Hegde, Aparna
    Khalil, Maya
    Mangla, Ankit
    Reese, Amy M.
    Ross, Merrick I.
    Poklepovic, Andrew S.
    Phan, Giao Q.
    Onitilo, Adedayo A.
    Yasar, Demet G.
    Powers, Benjamin C.
    Doolittle, Gary C.
    In, Gino K.
    Kokot, Niels
    Gibney, Geoffrey T.
    Atkins, Michael B.
    Shaheen, Montaser
    Warneke, James A.
    Ikeguchi, Alexandra
    Najera, Jose E.
    Chmielowski, Bartosz
    Crompton, Joseph G.
    Floyd, Justin D.
    Hsueh, Eddy
    Margolin, Kim A.
    Chow, Warren A.
    Grossmann, Kenneth F.
    Dietrich, Eliana
    Prieto, Victor G.
    Lowe, Michael C.
    Buchbinder, Elizabeth I.
    Kirkwood, John M.
    Korde, Larissa
    Moon, James
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (09): : 813 - 823
  • [5] Hyperprogression in advanced melanoma is not restricted to immunotherapy
    Fournier, Marie
    Mortier, Laurent
    Dereure, Olivier
    Dalac, Sophie
    Oriano, Bastien
    Dalle, Stephane
    Lebbe, Celeste
    [J]. EUROPEAN JOURNAL OF CANCER, 2023, 193
  • [6] Hyperprogression in advanced melanoma is not restricted to immunotherapy
    Yang, Fan
    Xu, Nan
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 199
  • [7] ECONOMIC EFFECTS OF DIFFERENT ADMINISTRATION SCHEME OF PEMBROLIZUMAB IN ADVANCED OR ADJUVANT MELANOMA
    Rossi, D.
    Marcellusi, A.
    Mennini, F. S.
    [J]. VALUE IN HEALTH, 2020, 23 : S448 - S449
  • [8] Pembrolizumab for patients with advanced melanoma
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2015, 16 (06): : E264 - E264
  • [9] Pembrolizumab for the treatment of advanced melanoma
    Burns, Michael C.
    O'donnell, Aidan
    Puzanov, Igor
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (08): : 867 - 873
  • [10] Pembrolizumab: A Review in Advanced Melanoma
    Deeks, Emma D.
    [J]. DRUGS, 2016, 76 (03) : 375 - 386
12345